Presentation is loading. Please wait.

Presentation is loading. Please wait.

Advancing the Development of Pediatric Therapeutics II: Evaluation of Long-term Neurocognitive Development in Pediatrics Lynne P. Yao, M.D. Acting Director,

Published bySpencer Hose Modified over 9 years ago

Similar presentations

Presentation on theme: "Advancing the Development of Pediatric Therapeutics II: Evaluation of Long-term Neurocognitive Development in Pediatrics Lynne P. Yao, M.D. Acting Director,"— Presentation transcript:

1 Advancing the Development of Pediatric Therapeutics II: Evaluation of Long-term Neurocognitive Development in Pediatrics Lynne P. Yao, M.D. Acting Director, Division of Pediatric and Maternal Health Office of New Drugs Center for Drug Evaluation and Research FDA

2 2 Pediatric Drug Development General Principles Pediatric patients should have access to products that have been appropriately evaluatedPediatric patients should have access to products that have been appropriately evaluated Product development programs should include pediatric studies when pediatric use is anticipatedProduct development programs should include pediatric studies when pediatric use is anticipated From FDA guidance to industry titled E11 - Clinical Investigation of Medicinal Products in the Pediatric Population, December 2000

3 3 Pediatric Drug Development Laws Best Pharmaceuticals for Children Act (BPCA)Best Pharmaceuticals for Children Act (BPCA) –Provides a financial incentive to companies to voluntarily conduct pediatric studies –FDA and the National Institutes of Health partner to obtain information to support labeling of products used in pediatric patients Pediatric Research Equity Act (PREA)Pediatric Research Equity Act (PREA) –Requires companies to assess safety and effectiveness of certain products in pediatric patients

4 4 Effect of Pediatric Legislation 563 Pediatric Labeling changes since enactment of BPCA and PREA563 Pediatric Labeling changes since enactment of BPCA and PREA –163 changes based on studies performed under BPCA –274 changes based on studies performed under PREA –76 changes based on studies performed under both BPCA and PREA Average of 37 labeling changes/year (2000-2014)Average of 37 labeling changes/year (2000-2014) –High in 2008 (58 labeling changes) –Low in 2003 (23 labeling changes)

5 5 Pediatric Labeling Changes (CDER and CBER) 1998-2014

6 Objectives of ADEPT Workshops Consider important drug development issues that are specific to pediatric patientsConsider important drug development issues that are specific to pediatric patients Seek input from important academic, industry, and patient and professional group stakeholdersSeek input from important academic, industry, and patient and professional group stakeholders Not intended to be an Advisory Committee meetingNot intended to be an Advisory Committee meeting Not intended to provide specific advice about a specific productNot intended to provide specific advice about a specific product

7 Objectives for Today What are the strengths and limitations of current tools and standards of measurement of neurocognitive and behavioral function in children?What are the strengths and limitations of current tools and standards of measurement of neurocognitive and behavioral function in children? How can short- and long-term neurocognitive and behavioral outcomes in pediatric patients be assessed?How can short- and long-term neurocognitive and behavioral outcomes in pediatric patients be assessed? Session I: Chair: Peter Como, M.D.Session I: Chair: Peter Como, M.D. –Review and discuss currently available measurement tools to assess normal neurocognitive development in children Session II: Chair: Philip Sheridan, M.D.Session II: Chair: Philip Sheridan, M.D. –Review and discuss neurocognitive safety signals identified in animal and human studies Session III: Chairs: Heather Adams, Ph.D., and Elsa Shapiro, Ph.D.Session III: Chairs: Heather Adams, Ph.D., and Elsa Shapiro, Ph.D. –Review and discuss strategies and study design considerations in the evaluation short- and long-term neurocognitive and behavioral outcomes in pediatric patients

8 Housekeeping Order lunch your lunch now!Order lunch your lunch now! –Order at the kiosk for $11.00 Cellphones and other noisy devices off!Cellphones and other noisy devices off! Facilities and amenitiesFacilities and amenities Please see our staff outside for any other questionsPlease see our staff outside for any other questions

9 Thanks To all of the distinguished speakers and panelistsTo all of the distinguished speakers and panelists To the planning committee, especially:To the planning committee, especially: –Heather Adams and Elsa Shapiro –Denise Pica-Branco –Len Kapcala and Philip Sheridan –Peter Como –Dianne Murphy and Ann McMahon

Download ppt "Advancing the Development of Pediatric Therapeutics II: Evaluation of Long-term Neurocognitive Development in Pediatrics Lynne P. Yao, M.D. Acting Director,"

Similar presentations

Daniel J. Isaacman, m.D., FAAP

Daniel J. Isaacman, m.D., FAAP
Strengthening the Medical Device Clinical Trial Enterprise

Strengthening the Medical Device Clinical Trial Enterprise
Risk Communication Advisory Committee Risk Communication Issues in the Food and Drug Administration Amendments Act of 2007 February 28, 2008.

Risk Communication Advisory Committee Risk Communication Issues in the Food and Drug Administration Amendments Act of 2007 February 28, 2008.
Advancing the Development of Pediatric Therapeutics (ADEPT) II: Evaluation of Long-term Neurocognitive Development in Pediatrics U.S. Food and Drug Administration.

Advancing the Development of Pediatric Therapeutics (ADEPT) II: Evaluation of Long-term Neurocognitive Development in Pediatrics U.S. Food and Drug Administration.
FDA and Communication about Regulated Products Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee August.

FDA and Communication about Regulated Products Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee August.
Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.

Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.
Oncologic Drugs Advisory Committee September 6, 2006 ODAC and the FDA Arms-Length or Arm-In-Arm? Abigail Alliance for Better Access to Developmental Drugs.

Oncologic Drugs Advisory Committee September 6, 2006 ODAC and the FDA Arms-Length or Arm-In-Arm? Abigail Alliance for Better Access to Developmental Drugs.
What’s New in the FDA’s Pharmaceutical Inspectorate and Risk Based Systems Inspection Rick Perlman Chair Food, Drug, and Cosmetic Division ASQ.

What’s New in the FDA’s Pharmaceutical Inspectorate and Risk Based Systems Inspection Rick Perlman Chair Food, Drug, and Cosmetic Division ASQ.
Introduction to Regulation

Introduction to Regulation
FDA Perspective Sally Loewke, M.D. Acting Division Director

FDA Perspective Sally Loewke, M.D. Acting Division Director
FDA’s Pharmaceutical Inspectorate Robert Coleman National Expert Drug Investigator Food and Drug Administration.

FDA’s Pharmaceutical Inspectorate Robert Coleman National Expert Drug Investigator Food and Drug Administration.
Washington State Hospital Association Medicaid Quality Incentive ER is for Emergencies Medicaid Quality Incentive ER is for Emergencies Web Conference.

Washington State Hospital Association Medicaid Quality Incentive ER is for Emergencies Medicaid Quality Incentive ER is for Emergencies Web Conference.
Joint NDAC/PAC meeting October 18, 2007 OTC Cold and Cough Products: Use in Children Advisory Committee Meeting October 18, 2007 Joel Schiffenbauer, MD.

Joint NDAC/PAC meeting October 18, 2007 OTC Cold and Cough Products: Use in Children Advisory Committee Meeting October 18, 2007 Joel Schiffenbauer, MD.
1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.

1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.
1 1 PDUFA & FDA Legislation FDA Regulatory & Compliance Symposium August 2006 Marc Wilenzick, Moderator for Panel: Dan Carpenter, Harvard Dept. of Government.

1 1 PDUFA & FDA Legislation FDA Regulatory & Compliance Symposium August 2006 Marc Wilenzick, Moderator for Panel: Dan Carpenter, Harvard Dept. of Government.
FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.

FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.
11 February 2008NLM BOR WG on Clinical Trials1 Clinical Trials Registration and Results Reporting: Legislative Requirements Jerry Sheehan Assistant Director.

11 February 2008NLM BOR WG on Clinical Trials1 Clinical Trials Registration and Results Reporting: Legislative Requirements Jerry Sheehan Assistant Director.
Quality In Investigational Drugs Presented by: Larry Parker, BSMT (ASCP), MHSA, ASQ CQA American Society for Quality Central Arkansas Section 1407.

Quality In Investigational Drugs Presented by: Larry Parker, BSMT (ASCP), MHSA, ASQ CQA American Society for Quality Central Arkansas Section 1407.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.

Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Science at the FDA: Update for the Science Board Jesse L. Goodman, MD, MPH Chief Scientist and Deputy Commissioner for Science and Public Health November.

Science at the FDA: Update for the Science Board Jesse L. Goodman, MD, MPH Chief Scientist and Deputy Commissioner for Science and Public Health November.

Similar presentations

Ads by Google